Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Faron Pharmaceuticals Share News (FARN)
FARN Share
Price
FARN Share
News
FARN Share
Chat
FARN Share
Trades3
FARN
Live RNS
FARN Share
Charts
FARN Level 2
Console
FARN Live
Share Price
FARN Broker
Ratings
FARN Directors
Deals
FARN Financial
Diary
FARN
Fundamentals
FARN Short
Positions
FARN
Media
FARN Company
Research
FARN Company
Timeline
Share Price Information for Faron Pharmaceuticals (FARN)
Last checked at -
Last checked at 
Intraday Faron Pharmaceuticals Share Chart
Faron Pharmaceuticals Notes Study Supporting Clevegen Programme
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said an article published in the Journal of Immunology has outlined the functional role of the company's Clever-1 treatment, part of its Clevegen cancer immunotherapy antibody programme.
Faron, which floated in London earlier this month, said the data published in the study supported Clever-1 as an immuosuppresive molecule and supports the use of Clevegen as an immunotherapy product.
"We are working hard to advance our Clevegen programme, as announced recently, towards clinical use as a new onco-immunological alternative," said Faron Chief Executive Markku Jalkanen.
Shares in Faron were trading flat at 275.00 pence on Monday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Latest FARN News
- IN BRIEF: Faron Pharma hails updated results from Matins study
17 Sep 2021 - TRADING UPDATES: Glenveagh, IOG swing to profit; Faron loss widens
26 Aug 2021 - Faron doses first patient in Covid-19 treatment trial
25 Aug 2021 - IN BRIEF: Faron Pharmaceuticals begins study of new Covid treatment
25 Aug 2021 - UK earnings, trading statements calendar - next 7 days
19 Aug 2021 - Faron Pharmaceuticals granted US patent for cancer immunotherapy drug
14 Jun 2021 - BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall
3 Jun 2021 - New research supports mode of action in Faron's 'MATINS' study
3 Jun 2021
Related News
IN BRIEF: Faron Pharmaceuticals fined EUR30,000 by Nasdaq Helsinki
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Says the Disciplinary Committee of Nasdaq Helsinki Ltd has imposed an EUR30,0...
WINNERS & LOSERS: James Cropper sees earnings up; Block sells stake
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday.
Faron Pharmaceuticals News
IN BRIEF: Faron Pharma hails updated results from Matins study
IN BRIEF: Faron Pharma hails updated results from Matins study
TRADING UPDATES: Glenveagh, IOG swing to profit; Faron loss widens
TRADING UPDATES: Glenveagh, IOG swing to profit; Faron loss widens
Faron doses first patient in Covid-19 treatment trial
(Sharecast News) - Clinical-stage biopharmaceuticals company Faron Pharmaceuticals announced on Wednesday that the first patient has been dosed in the...
IN BRIEF: Faron Pharmaceuticals begins study of new Covid treatment
IN BRIEF: Faron Pharmaceuticals begins study of new Covid treatment
UK earnings, trading statements calendar - next 7 days
UK earnings, trading statements calendar - next 7 days
Faron Pharmaceuticals granted US patent for cancer immunotherapy drug
Faron Pharmaceuticals granted US patent for cancer immunotherapy drug
BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall
BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall
New research supports mode of action in Faron's 'MATINS' study
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced the publication of research supporting the immunotherapeut...
Follow the stocks
